obesity drug news today glp-1 october 21 2025 The Age of Oral GLP-1s is Here Pharma Giants Bet on Next-Generation
Description
The monoclonal antibody drug Volagidemab is currently the only GCGR-targeting antagonist in clinical development
Its given weekly by injection and is often compared to GLP-1s because the effects (and side effects) overlap, but it tends to have stronger A1c reduction and weight loss effects
Research and Development Foundation of Dongguan Peoples Hospital (K202012)
Odyssey Behavioral Healthcare quietly sells to JLL Partners
[DOI] [PMC free article] [PubMed] [Google Scholar] 60.Wang W., Volkow N.D., Berger N.A., Davis P.B., Kaelber D.C., Xu R
Three distinct fragments of exendin 939 were found to reduce CAP-induced inward currents and calcium influx through TRPV1
